...nstriction]], [[aldosterone]] release, renal [[sodium reabsorption]] and [[vasopressin]] secretion. The AT<sub>2</sub> receptor also takes part in regulation of b
Saralasin was developed in the early 1970s and is an octapeptide analogue of Ang II, where the [[amino acids]] [[Aspartic acid|Asp]]<sup>1</sup>, [[I
...
22 KB (3,221 words) - 10:25, 28 March 2024
...nstriction]], [[aldosterone]] release, renal [[sodium reabsorption]] and [[vasopressin]] secretion. The AT<sub>2</sub> receptor also takes part in regulation of b
Saralasin was developed in the early 1970s and is an octapeptide analogue of Ang II, where the [[amino acids]] [[Aspartic acid|Asp]]<sup>1</sup>, [[I
...
22 KB (3,315 words) - 10:25, 28 March 2024
...tagonist|H<sub>2</sub>-受容体拮抗薬]], [[Cytoprotection|細胞保護剤]], [[prostaglandin analogue|プロスタグランジン類似体]]
...抗甲状腺薬物、[[calcitonin/ja|カルシトニン]]、[[diphosphonate/ja|ジホスホネート]]、[[vasopressin analogue/ja|バソプレシン類似物質]]
...
58 KB (1,845 words) - 17:09, 5 November 2023
...[[cytoprotectant|cytoprotectant]]s, [[prostaglandin analogue|prostaglandin analogue]]s.
...nin]], [[diphosphonate|diphosphonate]], [[vasopressin analogue|vasopressin analogue]]s.
...
52 KB (6,923 words) - 17:09, 5 November 2023
...[[cytoprotectant|cytoprotectant]]s, [[prostaglandin analogue|prostaglandin analogue]]s.
...nin]], [[diphosphonate|diphosphonate]], [[vasopressin analogue|vasopressin analogue]]s.
...
54 KB (7,245 words) - 17:08, 5 November 2023